ESPE Abstracts

Objective: Secondary osteoporosis has a high rate of accompanying chronic diseases. We aimed to review the clinical and laboratory features, underlying causes, Dual Energy X-ray Absorptiometry (DEXA) results before and after treatment of patients diagnosed with secondary osteoporosis and to determine the relationship between this condition and fracture rates.

Methods: This study was designed as a single-center, descriptive, cross-sectional retrospective study. A total of 70 patients diagnosed with secondary osteoporosis between 2019-2023 were included in the study.

Results: Of the 70 cases included in the study, 36 (51.4%) were male and 34 (48.6%) were female. The mean age was 10.37 ± 3.81 years. The mean height standard deviation score (SDS) was -3.0 ± 2.56 and BMI SDS was -0.15 ± 1.95. Oncological disease in 21 (30%) cases, nephrological in 11 (15.7%), hematological in 11 (15.7%), rheumatological in 15 (21.4%), neurological in 4 (5.7%) were detected and 8 (11.4%) had other diseases. The mean time to develop osteoporosis after the chronic disease was 5.76 ± 4.31 years. There was a history of steroid use in 35 (50%) cases, steroid and methotrexate in 16 (22.9%), methotrexate in 8 (11.4%), and antiepileptic drugs in 2 (2.9%) cases. While there were fractures in 7 (10%) cases at admission, it was absent in 62 (88.6%) cases. The fracture was observed in 1 patient (1.4%) during follow-up. It was not observed in 69 (98.6%). At admission, 24 (34.3%) had complaints, and 46 (65.7%) did not. In treatment, 62 (88.6%) received oral calcium and vitamin D, and 6 (8.6%) received intravenous bisphosphonates and vitamin D. The mean vertebral DEXA z score before treatment was -3.73 ± 0.94. Significant improvement was found when pre-treatment and 1st year of treatment, pre-treatment and 2nd year of treatment, 1st year and 2nd year of treatment were compared (P<0.05). When the pre-treatment and the second year of the treatment were compared, a significant increase was found in the serum calcium value (P<0.05). When the pre-treatment and the 2nd year of the treatment and the 1st and 2nd years of the treatment were compared, a significant decrease was found in the parathormone value (P<0.05).

Conclusion: In patients with chronic disease, the rate of detection of secondary osteoporosis without compliants is high due to medication side effects. For this reason, it is important to perform the necessary screening of patients in the risk group.